Evidence map›Paper›PMID 35160069›Full record

ReviewJournal of clinical medicine2022

Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease.

Camil Ciprian Mireștean, Constantin Volovăț, Roxana Irina Iancu, Dragoș Petru Teodor Iancu

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Adaptive radiotherapy for breast cancer.Clinical and translational radiation oncology · 2023
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Camil Ciprian MireșteanDepartment of Oncology and Radiotherapy, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0001-6212-8008
Constantin VolovățDepartment of Medical Oncology-Radiotherapy, Faculty of Medicine, "Gr. T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Roxana Irina IancuDepartment of Oral Pathology, Faculty of Dentistry, "Gr. T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Dragoș Petru Teodor IancuDepartment of Medical Oncology-Radiotherapy, Faculty of Medicine, "Gr. T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last decade, the analysis of the medical images has evolved significantly, applications and tools capable to extract quantitative characteristics of the images beyond the discrimination capacity of the investigator's eye being developed. The applications of this new research field, called radiomics, presented an exponential growth with direct implications in the diagnosis and prediction of response to therapy. Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with a severe prognosis, despite the aggressive multimodal treatments applied according to the guidelines. Radiomics has already proven the ability to differentiate TNBC from fibroadenoma. Radiomics features extracted from digital mammography may also distinguish between TNBC and non-TNBC. Recent research has identified three distinct subtypes of TNBC using IRM breast images voxel-level radiomics features (size/shape related features, texture features, sharpness). The correlation of these TNBC subtypes with the clinical response to neoadjuvant therapy may lead to the identification of biomarkers in order to guide the clinical decision. Furthermore, the variation of some radiomics features in the neoadjuvant settings provides a tool for the rapid evaluation of treatment efficacy. The association of radiomics features with already identified biomarkers can generate complex predictive and prognostic models. Standardization of image acquisition and also of radiomics feature extraction is required to validate this method in clinical practice.

Indexed as

biomarkerbreast cancerradiomicsTNBC

Identifiers

PMID35160069
PMCPMC8836903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.